Powder: -20°C for 3 years | In solvent: -80°C for 1 year
FtsZ-IN-4, an orally active inhibitor of FtsZ (filamenting temperature-sensitive mutant Z), demonstrates remarkable antibacterial activity and favorable pharmaceutical properties. With low cytotoxicity (CC 50 <20 μg/mL) [1], FtsZ-IN-4 exhibits promising potential for therapeutic applications.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 1,520.00 | |
50 mg | 10-14 weeks | $ 1,980.00 | |
100 mg | 10-14 weeks | $ 2,500.00 |
Description | FtsZ-IN-4, an orally active inhibitor of FtsZ (filamenting temperature-sensitive mutant Z), demonstrates remarkable antibacterial activity and favorable pharmaceutical properties. With low cytotoxicity (CC 50 >20 μg/mL) [1], FtsZ-IN-4 exhibits promising potential for therapeutic applications. |
In vitro | FtsZ-IN-4, identified as compound 30, exhibits potent antibacterial effects against B. subtilis and S. aureus, with minimum inhibition concentrations (MIC) of 0.008-0.25 μg/mL, according to standards [1]. This compound demonstrates rapid bactericidal activity, achieving significant reductions in bacterial population within 3 hours at concentrations of 0.064 μg/mL or 0.5 μg/mL, with minimum bactericidal concentration (MBC) to MIC ratios of ≤4, indicating efficacy within Clinical and Laboratory Standards Institute (CLSI) guidelines [1]. Additionally, at concentrations exceeding 20 μg/mL over 72 hours, FtsZ-IN-4 shows minimal cytotoxicity towards Vero cells, with a 50% cytotoxic concentration (CC50) >20 μg/mL [1]. It notably disrupts bacterial cell division, elongating B. subtilis ATCC9372 within 3 hours at 0.016 μg/mL and induces aberrant cell division leading to bacterial cell death [1]. Furthermore, FtsZ-IN-4 enhances SaFtsZ polymerization at 10 μg/mL within 0-15 minutes and inhibits SaFtsZ's GTPase activity in a dose-dependent manner within 30 minutes across concentrations of 0-35 μg/mL [1]. In cell proliferation assays, the compound significantly decreased populations of S. aureus ATCC25923 and B. subtilis ATCC9372 to below detectable limits within 3 hours at multiples of the MIC, establishing its effective bactericidal capabilities [1]. |
In vivo | FtsZ-IN-4 (compound 30) demonstrates moderate pharmacokinetic exposure (AUC (0-t) = 544.2 h*ng/mL) and an oral bioavailability (F) of 61.2% following a 5 mg/kg oral (p.o.) administration in mice [1]. Administered intravenously (i.v.) at a dose of 25 mg/kg, it shows significant in vivo efficacy, reducing bacterial burden in male ICR mice infected with S. aureus ATCC25923 to levels comparable with vancomycin, as evidenced by its pharmacokinetic profile which includes a half-life (T 1/2) of 0.28 hours and a peak concentration (Cmax) of 480.5 ng/mL following a 1 mg/kg dose, and enhanced exposure metrics (AUC (0-t) = 544.2 h*ng/mL) at a 5 mg/kg dose, confirming its effectiveness as an intraperitoneal injection [1]. |
Molecular Weight | 387.81 |
Formula | C21H16ClF2NO2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.